Here’s Why Immune Design is Down 6.8% Since the Last Earnings Report

Immune Design is Down 6.8%

Plummeting 6.8%, way outperforming the market, Immune Design Corp. (NASDAQ:$IMDZ)’s shares are suffering a serious outlook.

Let’s take a look back on Immune Design’s last earnings report.

Narrower-than-expected Loss in Q2

The company incurred 2Q17 Loss of 54 cents per share, narrower than the Zacks Consensus Estimate of 65 cents.

2Q17

  • The company’s total revenue was $0.7 million, down from $1.1 million in the year ago quarter
  • Research and development expenses were down 4.6% to $10.9 million
  • General and administrative expenses decreased by 1.5% to $3.9 million

Pipeline

Immune Design is developing multiple new products using its two discovery platforms, ZVex and GLAAS, in the field of immuno-oncology.

Of the two products, CMB305 is currently in trials, although data has not been optimal. The other, G100, is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study. In this trial, over a third of patients have achieved a partial response, and 50% of evaluable patients experience shrinkage of untreated distal lesions.

New Estimates

In the past month, investors have seen a downward trend in fresh estimates. At this time, Immune sees a new Growth Score of B. The stock sees a grade of F on the value side, situating it in the fifth quintile for investment strategy. Hence, the company’s stock is suitable for growth and momentum investors.

Featured Image: twitter

About the author: Jennifer is a University of Western Ontario graduate with a degree in International Business. She strives to excel as a content creator in the digital sphere, working with clients in the Finance and Tech industry to leverage clickable taglines, images, and articles in driving traffic. When not writing, Jennifer enjoys photography, copywriting, and video production.